OCT 03, 2018 6:00 AM PDT

Identification of Pre-existing Adaptive Immune Responses to Cas9 in Humans

Presented at: CRISPR 2018
Speaker
  • PhD Student in Stem Cell Biology and Regenerative Medicine, Stanford University
    Biography
      Dr. Charlesworth grew up in Australia and moved to the US in 2008. He went to Humboldt State for undergrad where he obtained his bachelors in molecular biology & zoology in 2015. After completing his bachelors he started a CIRM Bridges stem cell internship at Stanford in 2015 in the lab of Dr. Matthew Porteus where he worked on the development of genome editing in Hematopoietic Stem Cells and identified the presence of pre-existing adaptive immune responses to Cas9 in humans. In September of 2017 he started a PhD in Stem Cell and Regenerative Medicine at Stanford and is now a graduate student in the Nakauchi lab.

    Abstract

    The CRISPR-Cas9 system has proven to be a powerful tool for genome editing allowing for the precise modification of specific DNA sequences within a cell. Many efforts are currently underway to use the CRISPR-Cas9 system for the therapeutic correction of human genetic diseases. The most widely used homologs of the Cas9 protein are derived from the bacteria Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes). Based on the fact that these two bacterial species cause infections in the human population at high frequencies, we looked for the presence of pre-existing adaptive immune responses to their respective Cas9 homologs, SaCas9 (S. aureus homolog of Cas9) and SpCas9 (S. pyogenes homolog of Cas9). We have identified the presence of pre-existing humoral immune responses to SaCas9 and SpCas9 by both Western Blot and ELISA. In addition we have also identified pre-existing cellular responses to Cas9 by intracellular cytokine staining and ELISPOT. 

    Learning Objectives: 

    1. Pre-existing adaptive immunity to the most commonly used homologous of Cas9 is prevalent
    2. Potential immune responses to any new therapeutic should be considered when considering any kind of in-vivo therapy


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources
    Attendees
    • See more